Sanofi, Regeneron to develop cancer immunotherapies

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) entered a five-year deal under which the partners will jointly develop and commercialize immuno-oncology candidates including PD-1 inhibitor REGN2810 and a pipeline of preclinical monoclonal and bi-specific antibodies. Regeneron began a Phase I study of REGN2810 in 1Q15.

While REGN2810 lags behind other clinical and marketed PD-1 and PD-L1 inhibitors, Regeneron President and CEO Leonard Schleifer said in January that having checkpoint inhibitors and antibody candidates "under one roof" would allow the company to have more control over the price of combination therapies. ...